Dr. Reddy’s Stock Rise After Key Biosimilar Approval – Analyzed
Dr. Reddy’s Laboratories saw a positive increase of 1.55% in its stock price, reaching Rs 1,243.70. This jump happened because the European Commission (EC) gave Dr. Reddy’s permission to sell a new medicine called AVT03. AVT03 is similar to two other medicines, Prolia and Xgeva, which are used to help people with weak bones.
Key Points
- AVT03, a biosimilar, received EC approval, boosting Dr. Reddy’s stock.
- It’s similar to Prolia and Xgeva, used for bone health issues.
- Prolia treats osteoporosis in men and women after menopause.
- Xgeva prevents bone problems in cancer patients and treats giant cell tumors.
- EU and EEA countries (Iceland, Liechtenstein, Norway) gain access to AVT03.
- Dr. Reddy’s & Alvotech partnership drives AVT03’s commercialization globally.
Prolia is mainly used for women and men who have trouble keeping their bones strong. It’s often given to people who have gone through menopause or who are at higher risk of fractures due to hormone treatments, like those with prostate cancer. Xgeva is used to stop bone problems when cancer spreads to the bones and to treat a specific type of bone tumor.
The good news is that the European Commission’s approval means that AVT03 can be sold in all countries within the European Union, plus countries like Iceland, Liechtenstein, and Norway. Dr. Reddy’s works with another company, Alvotech, to make and sell this new medicine.
Dr. Reddy’s Laboratories is a large company that makes many different medicines, including active ingredients (APIs), generic drugs, brand-name drugs, biosimilars, and over-the-counter medications. Their recent financial results show a strong increase in profits and revenue, indicating healthy growth.
Specifically, Dr. Reddy’s net profit increased by 7.3% to Rs 1,347.10 crore, and their total sales rose by 9.8% to Rs 8,804.90 crore during the last quarter. This shows that the company is doing well and creating value for its investors.
This biosimilar approval represents a significant step towards accessible and affordable bone health treatments for patients across Europe.
